79 related articles for article (PubMed ID: 22633552)
1. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
Michalski J; Winter K; Roach M; Markoe A; Sandler HM; Ryu J; Parliament M; Purdy JA; Valicenti RK; Cox JD
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e363-70. PubMed ID: 22633552
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.
Zhu Z; Zhang J; Liu Y; Chen M; Guo P; Li K
Br J Cancer; 2014 May; 110(10):2396-404. PubMed ID: 24736585
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.
Spratt DE; Pei X; Yamada J; Kollmeier MA; Cox B; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):686-92. PubMed ID: 22795805
[TBL] [Abstract][Full Text] [Related]
4. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Lawton CAF; Lin X; Hanks GE; Lepor H; Grignon DJ; Brereton HD; Bedi M; Rosenthal SA; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Kim H; Parliament MB; Rabinovitch R; Roach M; Kwok Y; Dignam JJ; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):296-303. PubMed ID: 28463149
[TBL] [Abstract][Full Text] [Related]
5. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.
Murray CJ; Atkinson C; Bhalla K; Birbeck G; Burstein R; Chou D; Dellavalle R; Danaei G; Ezzati M; Fahimi A; Flaxman D; Foreman ; Gabriel S; Gakidou E; Kassebaum N; Khatibzadeh S; Lim S; Lipshultz SE; London S; Lopez ; MacIntyre MF; Mokdad AH; Moran A; Moran AE; Mozaffarian D; Murphy T; Naghavi M; Pope C; Roberts T; Salomon J; Schwebel DC; Shahraz S; Sleet DA; Murray ; Abraham J; Ali MK; Atkinson C; Bartels DH; Bhalla K; Birbeck G; Burstein R; Chen H; Criqui MH; Dahodwala ; Jarlais ; Ding EL; Dorsey ER; Ebel BE; Ezzati M; Fahami ; Flaxman S; Flaxman AD; Gonzalez-Medina D; Grant B; Hagan H; Hoffman H; Kassebaum N; Khatibzadeh S; Leasher JL; Lin J; Lipshultz SE; Lozano R; Lu Y; Mallinger L; McDermott MM; Micha R; Miller TR; Mokdad AA; Mokdad AH; Mozaffarian D; Naghavi M; Narayan KM; Omer SB; Pelizzari PM; Phillips D; Ranganathan D; Rivara FP; Roberts T; Sampson U; Sanman E; Sapkota A; Schwebel DC; Sharaz S; Shivakoti R; Singh GM; Singh D; Tavakkoli M; Towbin JA; Wilkinson JD; Zabetian A; Murray ; Abraham J; Ali MK; Alvardo M; Atkinson C; Baddour LM; Benjamin EJ; Bhalla K; Birbeck G; Bolliger I; Burstein R; Carnahan E; Chou D; Chugh SS; Cohen A; Colson KE; Cooper LT; Couser W; Criqui MH; Dabhadkar KC; Dellavalle RP; Jarlais ; Dicker D; Dorsey ER; Duber H; Ebel BE; Engell RE; Ezzati M; Felson DT; Finucane MM; Flaxman S; Flaxman AD; Fleming T; Foreman ; Forouzanfar MH; Freedman G; Freeman MK; Gakidou E; Gillum RF; Gonzalez-Medina D; Gosselin R; Gutierrez HR; Hagan H; Havmoeller R; Hoffman H; Jacobsen KH; James SL; Jasrasaria R; Jayarman S; Johns N; Kassebaum N; Khatibzadeh S; Lan Q; Leasher JL; Lim S; Lipshultz SE; London S; Lopez ; Lozano R; Lu Y; Mallinger L; Meltzer M; Mensah GA; Michaud C; Miller TR; Mock C; Moffitt TE; Mokdad AA; Mokdad AH; Moran A; Naghavi M; Narayan KM; Nelson RG; Olives C; Omer SB; Ortblad K; Ostro B; Pelizzari PM; Phillips D; Raju M; Razavi H; Ritz B; Roberts T; Sacco RL; Salomon J; Sampson U; Schwebel DC; Shahraz S; Shibuya K; Silberberg D; Singh JA; Steenland K; Taylor JA; Thurston GD; Vavilala MS; Vos T; Wagner GR; Weinstock MA; Weisskopf MG; Wulf S; Murray ;
JAMA; 2013 Aug; 310(6):591-608. PubMed ID: 23842577
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
Nini A; Gandaglia G; Fossati N; Suardi N; Cucchiara V; Dell'Oglio P; Cazzaniga W; Luzzago S; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):777-84. PubMed ID: 25959166
[TBL] [Abstract][Full Text] [Related]
7. Creation, evolution, and future challenges of ion beam therapy from a medical physicist's viewpoint (Part 3): Chapter 3. Clinical research, Chapter 4. Future challenges, Chapter 5. Discussion, and Conclusion.
Endo M
Radiol Phys Technol; 2023 Dec; 16(4):443-470. PubMed ID: 37882992
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity.
Miszczyk M; Kraszkiewicz M; Moll M; Kaminiów K; Sobel S; Dolla Ł; Wojcieszek P; Rajwa P; Yanagisawa T; Nowicka Z; Shariat SF; Goldner G; Miszczyk L; Majewski W
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831523
[TBL] [Abstract][Full Text] [Related]
9. Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.
Muralidhar A; Potluri HK; Jaiswal T; McNeel DG
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678880
[TBL] [Abstract][Full Text] [Related]
10. Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
McDonald AM; DeMora L; Yang ES; Hoyle JM; Lenzie A; Williams GR; Michalski JM; Yee D; Bahary JP; Den RB; Roach M; Dess R; Mishra MV; Valicenti RK; Lau HY; Marcrom SR; Souhami L; Mendez LC; Chen Y; Doncals DE; Pugh SL; Feng FY; Sandler HM
Cancer; 2023 Mar; 129(5):685-696. PubMed ID: 36579470
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome.
Ryg U; Seierstad T; Nilsen LB; Hellebust TP; Djupvik LH; Gustafson H; Hydal J; Kishan AU; Hole KH; Lilleby W
Front Oncol; 2022; 12():861127. PubMed ID: 35463376
[TBL] [Abstract][Full Text] [Related]
12. Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer.
Chen L; Gannavarapu BS; Desai NB; Folkert MR; Dohopolski M; Gao A; Ahn C; Cadeddu J; Bagrodia A; Woldu S; Raj GV; Roehrborn C; Lotan Y; Timmerman RD; Garant A; Hannan R
Front Oncol; 2022; 12():779182. PubMed ID: 35265519
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
[TBL] [Abstract][Full Text] [Related]
14. Biochemical recurrence prediction after radiotherapy for prostate cancer with T2w magnetic resonance imaging radiomic features.
Dinis Fernandes C; Dinh CV; Walraven I; Heijmink SW; Smolic M; van Griethuysen JJM; Simões R; Losnegård A; van der Poel HG; Pos FJ; van der Heide UA
Phys Imaging Radiat Oncol; 2018 Jul; 7():9-15. PubMed ID: 33458399
[TBL] [Abstract][Full Text] [Related]
15. Impact of Inter-fractional Anatomical Changes on Dose Distributions in Passive Carbon-Ion Radiotherapy for Prostate Cancer: Comparison of Vertical and Horizontal Fields.
Yokoyama A; Kubota Y; Kawamura H; Miyasaka Y; Kubo N; Sato H; Abe S; Tsuda K; Sutou T; Ohno T; Nakano T
Front Oncol; 2020; 10():1264. PubMed ID: 32850384
[No Abstract] [Full Text] [Related]
16. Salvage I-125 brachytherapy for locally-recurrent prostate cancer after radiotherapy.
Pons-Llanas O; Burgos-Burgos J; Roldan-Ortega S; Conde-Moreno A; Celada-Alvarez F; Ruiz-Martinez JC; Lliso-Valverde F; Tormo-Micó A; Perez-Calatayud J; López-Torrecilla J
Rep Pract Oncol Radiother; 2020; 25(5):754-759. PubMed ID: 32684865
[TBL] [Abstract][Full Text] [Related]
17. Multi-Institutional Analysis of Synchronous Prostate and Rectosigmoid Cancers.
Jacobs CD; Trotter J; Palta M; Moravan MJ; Wu Y; Willett CG; Lee WR; Czito BG
Front Oncol; 2020; 10():345. PubMed ID: 32266135
[No Abstract] [Full Text] [Related]
18. Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial.
Macias VA; Barrera-Mellado I
BJU Int; 2020 Feb; 125(2):215-225. PubMed ID: 31614071
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor.
Umezawa R; Inaba K; Nakamura S; Wakita A; Okamoto H; Tsuchida K; Kashihara T; Kobayashi K; Harada K; Takahashi K; Murakami N; Ito Y; Igaki H; Jingu K; Itami J
Asian J Urol; 2019 Apr; 6(2):192-199. PubMed ID: 31061806
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
